本文選題：結直腸癌 + 化療方案　； 參考：《中國醫(yī)院藥學雜志》2017年22期

【摘要】：目的:探討轉移性結直腸癌(mCRC)3種一線化療方案的藥物經(jīng)濟學效果及影響因素。方法:采用回顧性調查方法,納入2012年1月1日-2015年10月30日期間符合納入標準的mCRC患者,根據(jù)化療方案不同分為FOLFOX組、CapeOx組和FOLFIRI組。以總住院費用為成本,無進展生存時間(PFS)為效果,對3種化療方案進行成本-效果分析和敏感度分析,并評價化療藥物是否國產(chǎn)及醫(yī)保支付對結果的影響。結果:共納入678名患者,FOLFOX組(136例)、CapeOx組(392例)和FOLFIRI組(150例)間基本情況無統(tǒng)計學差異(P0.05),具有可比性。FOLFOX組、CapeOx組和FOLFIRI組PFS分別為154.15 d、156.16 d和165.84 d,不良反應各組間無統(tǒng)計學差異,總治療費用分別為63 956.11元、73 826.06元和79 259.20元,成本-效果比分別為414.90、472.76和477.93。在FOLFOX方案的基礎上,每增加一天PFS,FOLFIRI方案和CapeOx方案所追加的成本分別為57.86元和59.69元。敏感度分析結果與成本-效果分析一致。亞組分析表明,國產(chǎn)藥物的效果略低于進口藥物,成本均高于進口藥物,成本-效果比低于進口藥物,藥物經(jīng)濟學效果好。3種方案患者自付費用成本-效果比FOLFOX方案CapeOx方案FOLFIRI方案,醫(yī)保支付費用成本-效果比FOLFOXFOLFIRICapeOx。結論:mCRC3種一線化療方案中,成本最低的為FOLFOX方案,效果最佳的為FOLFIRI方案,經(jīng)濟學效果最優(yōu)為FOLFOX方案。
[Abstract]:Objective: to investigate the pharmacoeconomic effects and influencing factors of three first-line chemotherapy regimens for metastatic colorectal cancer (mCRC). Methods: according to the chemotherapy regimen, mCRC patients who met the inclusion criteria from January 1, 2012 to October 30, 2015 were divided into FOLFOX group (CapeOx group) and FOLFIRI group (FOLFOX group). Taking total hospitalization cost as the cost and PFS as the effect, the cost-effect analysis and sensitivity analysis of three chemotherapy regimens were carried out, and the effects of domestic chemotherapeutic drugs and medical insurance payment on the results were evaluated. Results: there was no statistical difference between the two groups (P 0.05). The PFS of CapeOx group (392 cases) and FOLFIRI group (150 cases) were comparable (P0.05). The PFS of CapeOx group and FOLFIRI group were 154.15 days 156.16 days and 165.84 days, respectively. The total cost of treatment was 63 956.11 yuan 73 826.06 yuan and 79 259.20 yuan respectively. The cost-effectiveness ratio was 414.90472.76 and 477.93 respectively. On the basis of FOLFOX scheme, the additional cost of PFSU FOLFIRI scheme and CapeOx scheme is 57.86 yuan and 59.69 yuan respectively. Sensitivity analysis results are consistent with cost-effect analysis. Subgroup analysis showed that the effect of domestic drugs was slightly lower than that of imported drugs, and the cost was higher than that of imported drugs, and the cost-effect ratio was lower than that of imported drugs. Pharmacoeconomics is better than FOLFOX, CapeOx, FOLFIRI, and Medicare, which is more effective than FOLFOXFOLFIRICapeOx. Conclusion the lowest cost is FOLFOX, the best is FOLFIRI, and the best in economics is FOLFOX.
【作者單位】： 南京醫(yī)科大學第一附屬醫(yī)院藥學部;
【基金】：江蘇省藥學會奧賽康臨床藥學基金(編號:201308)
【分類號】：R956

【相似文獻】

相關期刊論文 前10條

1 陸志城;貝伐單抗:一種治療轉移性結直腸癌的新藥[J];中國處方藥;2005年05期

2 馬愛霞;曾靚;;各國藥物經(jīng)濟學評價指南及對我國的啟示[J];上海醫(yī)藥;2006年06期

3 岳曉萌;叢博;吳久鴻;;藥物經(jīng)濟學評價的應用與重要性[J];首都醫(yī)藥;2014年04期

4 郭慧玲,鄒雄智;藥物經(jīng)濟學評價研究中若干問題探討[J];企業(yè)經(jīng)濟;2002年05期

5 龔向光,胡善聯(lián);澳大利亞藥物經(jīng)濟學評價指南介紹[J];衛(wèi)生經(jīng)濟研究;2002年06期

6 陳文,高繼明,畢康寧,楊莉;國內藥物經(jīng)濟學評價研究文獻的系統(tǒng)評估[J];中國藥房;2004年01期

7 楊莉;;國外藥物經(jīng)濟學評價應用現(xiàn)狀與發(fā)展趨勢[J];中國執(zhí)業(yè)藥師;2008年08期

8 張芳;陳安進;崔衛(wèi)華;;藥物經(jīng)濟學評價系統(tǒng)的開發(fā)與應用[J];中國藥房;2008年02期

9 李明暉;李洪超;馬愛霞;;我國藥物經(jīng)濟學評價研究的現(xiàn)狀、問題及建議[J];中國藥房;2008年11期

10 孫利華;李靜;;我國藥物經(jīng)濟學評價常見問題及其改進建議[J];中國新藥雜志;2008年12期

相關會議論文 前3條

1 彭曉霞;;路徑分析在藥物經(jīng)濟學評價中的應用[A];2012全國藥物流行病學學術年會報告資料集[C];2012年

2 周俊翔;余文韜;徐s，

本文編號：2092514